Investor Presentaiton
Key challenge for (bio-)pharmaceutical products
Key challenge:
Medical safety
Medication safety is key and (cross-)
contamination unacceptable
Key contamination sources:
Air particles
Input: Raw materials,
containers, closures
Personnel
Products:
Injectables
Cancer drugs (ADC, Cytotoxics)
Cell & gene therapy (Advanced
Therapy Medicinal Products (ATMPS))
Hormones: Insulin
Medical drugs (Thrombosis, EPO,
blood plasma products, botox, etc.)
Vaccines: Flu, COVID-19, etc.
November 2023
SKAN Group AG Investor Presentation
Increased infection risk as their
application bypasses many of the
human body's natural defenses
A
STERILE
SLE USE E
In particular true for:
High-value biopharma
drugs
Risk of significant economic
losses if high-value biopharma drugs
get contaminated
Risk of cross-contamination
increases with small batch size of
fast-growing personalized medicine
3
SKANView entire presentation